Simplifying and Demystifying True and False Contraindications

Robert M Jacobson, MD Medical Director, Primary Care Immunization Program, Rochester, Kasson, and Southeast Minnesota April 25, 2024

- Identify common false contraindications
- List the steps in finding the true contraindications
- State why the package inserts fail as resources

Definition of Contraindication

- Condition puts recipient at risk for serious harm
- Prohibition against getting a vaccine
- Not subject to clinical judgment
- Basis for malpractice

- History of a serious allergic reaction or anaphylaxis
 - To a previous dose of the vaccine in question
 - To a constituent of the vaccine in question
- Personal history and not family history
- Anaphylaxis harbinger of life-threatening allergy
 - Two or more organ systems
 - Skin, respiratory, cardiologic, or gastrointestinal

A Related Definition

Precaution

- Condition calls for provider-patient consideration
 - Might put recipient at risk for serious harm
 - Might cause diagnostic confusion
 - Might compromise response to the vaccine
- Need to weigh individual risks and benefits

Acute moderate to severe illness

- With fever
- Without fever
- Moderate = interfere/delay activities of daily living
- Severe = prevent activities of daily living
- Often better to await until acute phase resolves
- Avoids confusing illness with adverse effects
- However, not a contraindication

The Impact of False Contraindications

- All too often patients go unvaccinated
- Healthcare staff often complicit by not addressing
- Misinformation can have a long-lasting impact

Examples of Universal False Contraindications

- Mild acute illness with or without fever
 - Mild = symptoms do not interfere or prevent
- Mild-to-moderate local reaction after previous dose
- No recent physical exam in well-appearing person
- Fever after previous dose
- Convalescent phase of illness

More Universal False Contraindications

- Recent exposure to an infectious disease
- History of penicillin allergy
- History of other non-vaccine allergies
- Relatives with allergies to the vaccine
- Receiving allergen extract immunotherapy

Nearly Universal False Contraindications

- Antimicrobial therapy (all but live typhoid vaccine)
- Preterm birth (except HepB vaccine if <2000 g)
- History of Guillain-Barre Syndrome
 - Except* if within 6 weeks of tetanus vaccine OR
 - Except* if within 6 weeks of previous flu vaccine

*Not a contraindication but a precaution

Where Do We Find True Contraindications

- Advisory Committee in Immunization Practices
 ACIP
 - Technical Advisor to US Public Health Service
 - Established in 1964
 - Not just recommendations for immunizations
 - Also contraindications and precautions
 - Recommendations published in CDC's MMWR

More on the ACIP

• Only federal source of vaccine recommendations

- Exception military
- ACIP and not FDA
- Recommendations official
- Meet at least three times a year
 - Consider not just licensure data for efficacy, safety
 - Also limits vaccine use by demonstrated need
 - No other licensed drug or device has this standard

ACIP Recommendations and Immunization Safety

- FDA requires safety versus placebo at licensure
- FDA monitors post licensure quality of manufacture
- Also FDA, CDC, & ACIP monitor immunization safety
 - Passive reports with VAERS
 - Active monitoring with Vaccine Safety Datalink
 - •V-safe
 - CISA for adverse events consultation
 - Vaccine pregnancy registries (e.g. COVID)

Comparison with Other Health Care Products

Product	Proof of Efficacy by Placebo- Controlled Trials	Proof of Safety by Placebo- Controlled Trials	Proof of Epidemiologic Need in Current US Population	Proof of a Lack of Available Reasonable Alternatives
Vitamins and minerals	No	No	No	No
Probiotics and other nutraceuticals	No	No	No	No
FDA licensed drugs and devices	Yes	Yes	No	No
Vaccines and immunizations	Yes	Yes	Yes	Yes

The Broadening of the ACIP Reach

Harmonized recommendations in 1995

- Centers for Disease Control and Prevention (CDC)
- Food and Drug Administration or FDA
- Major independent academic medical academies
- Arbiter of Vaccines for Children coverage
- Arbiter for Affordable Care Act coverage
 - Immunizations as preventive services
 - First dollar coverage

Best Source of Contraindications and Precautions

- Go to cdc.gov/vaccines
- Scroll down to find For Professionals
- Click Healthcare Professionals
- Scroll down to ACIP Recommendations and click it
- Find the left-hand nav bar
- Find Comprehensive Recommendations & Guidelines
- Click it





Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People™

Search

Vaccines & Immunizations

Print

and the second				s 18 Years or Younger, United States, 2024	Table 1 Recommende	ed Adult Immunization	ichedule by Age Group, Ur	nited States, 2024		COVID	_19
lo-determine minimum intervals betwee	endoses, we the catch-up	schedule (Table 2).	I behind or start late, provide catch-up vaccination a	at the earliest opportunity as indicated by the green bars.	Vaccine	19-26 years	27-49 years	50-64 years	≥65 years	COVID	-12
Vectors and off-se investiging agents Responsiony specyfiel sine (111) endy Nineseinska	Brits 1 me 2 me		M Trans TS must TS must <thts must<="" th=""> <thts must<<="" th=""><th>naa 2-3yni 4-4yni 2-18yni 13-13yni 13-15yni 18yni 17-18yni</th><th>COVID-19</th><th></th><th>T or more doses of upd</th><th>aled (2023-2024 Formula) vaccine (See N</th><th>kitesi</th><th></th><th></th></thts></thts>	naa 2-3yni 4-4yni 2-18yni 13-13yni 13-15yni 18yni 17-18yni	COVID-19		T or more doses of upd	aled (2023-2024 Formula) vaccine (See N	kitesi		
(KSV mAb (Ninserimab) Hepetitis B (Hepet)	1"dow e	Concession of Concession, Name	Pag		Influenza inactivated (IVI) or Influenza recombinant (IVI)		1 dose and	veally			
Reference (RV) RV1 (2 doos carles), RV5 (2 doos carles)	14	ar 2ªdae Secti	den .		Influenza live, attenuated	1 dose a	пш8у				
Dightharia, talanun, acaillaíar partumite (D'fait-c'7 ym)	154	a 24daa 34d	ePåse	P des	Respiratory Syncytial Virus	Seasonal administration du	in a consideration of the Midday		>60 years		-
Assemptifies influenzas type is (Hill)		ne 2ªdine Seela	ates For Passa		(RSV)		ing programs, see notes. I dose Tdap each programsy: 1 dose 7d/7d		a second and a second		FO
Prevencessoral conjugate (PCV15, PCV20)	ra.	a 25.6me 25.6	e Cdue+		(Tdap or Td)		1 dose Tdup, then Td or Tdup			0.0	
Inscittuted polynomy (PV c18 pro)	1. ar	a 24.6m a-	Y* 614		Measles, mamps, rabella		1 or 2 doses depending a in born in 1957 or	e Indication later)	For healthcare personnel, see notes	XY	an
2024	lmn	nui	nizatior	Schedules	Vertrolle Critty Salte tecnologie Salt Herrin pagthacotive	a team a team E team à team a search a	a land) Ming investigation (land name) All Menorgh (K) poors	345 34			
2024											



Children (Birth to 18 Years)



Pregnancy



What's this?




Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People™

Search

Healthcare Providers / Professionals

Print









Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People™

Search

Vaccine Recommendations and Guidelines of the ACIP

ACIP Recs Home

ACIP Recs Home

- Vaccine-Specific + Recommendations
- Recs Listed by Date
- Comprehensive Recommendations and Guidelines

Archived ACIP Recs

1

ACIP Vaccine Recommendations Guidelines

Advisory Committee on Immunization Practices (ACIP)

<u>Print</u>

+







പ

Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People™

Search

Vaccine Recommendations and Guidelines of the ACIP

ACIP Recs Home



Vaccine-Specific Recommendations

Recs Listed by Date

Comprehensive Recommendations and Guidelines

> General Best Practice + Guidelines

Archived ACIP Recs

Comprehensive Recommendation Guidelines

<u>Print</u>

Advisory Committee on Immunization Practices (ACIP)

- <u>General Best Practice Guidelines for Immunization</u>
- *MMWR*, November 25, 2011, Vol 60, #RR07 Immunization of Health-Care Personnel
 - <u>Print version</u> 📕 [48 pages]

This report updates the previously published summary of recomment health-care personnel (HCP) in the United States (1997). This report su

- General Best Practice Guidelines for Immunization
- Click it
- Scroll down to Contraindications and Precautions
- Click it
- Scroll down to Table 4-1
- Organized by vaccine
- Lists contraindications and precautions for each





പ

Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People™

Search

Vaccine Recommendations and Guidelines of the ACIP

ACIP Recs Home



Vaccine-Specific Recommendations

Recs Listed by Date

Comprehensive Recommendations and Guidelines

> General Best Practice + Guidelines

Archived ACIP Recs

Comprehensive Recommendation Guidelines

<u>Print</u>

Advisory Committee on Immunization Practices (ACIP)

- <u>General Best Practice Guidelines for Immunization</u>
- *MMWR*, November 25, 2011, Vol 60, #RR07 Immunization of Health-Care Personnel
 - <u>Print version</u> 📕 [48 pages]

This report updates the previously published summary of recomment health-care personnel (HCP) in the United States (1997). This report su

A 🗔 🗘



Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People™

Search

Vaccine Recommendations and Guidelines of the ACIP

ACIP Recs Home > Comprehensive Recommendations and Guidelines

ACIP Recs Home

Vaccine-Specific Recommendations

Recs Listed by Date

Comprehensive Recommendations and Guidelines

General Best Practice Guidelines

General Best Practice Guidelines Immunization

<u>Print</u>

Updated August 1, 2023

Best Practices Guidance

Kroger A, Bahta L, Long S, Sanchez P

Printer friendly version 📙 [1.23 MB, 198 pages]

Introduction

History

 \square

Timing and Spacing of Immunobiologics

Contraindications and Precautions

Preventing and Managing Adverse Reactions

Vaccine Administration

Storage and Handling of Immunobiologics

Altered Immunocompetence

Special Situations

14 1 AL B

Vaccinations Records

Introduction

Purpose and topics covered in this report...

History

History of development of: Timing and Spacing, Contraindications and Precautions, Preventing and Managing Adverse Reactions...

Timing and Spacing of Immunobiologics

Vaccine scheduling, supply and lapsed schedule, spacing of doses, simultaneous and nonsimulaneous administration, licensed combination vaccines, interchangeability of formulations, extra doses, conjugate vaccines...

Contraindications and Precautions

General principles, standards of valid contraindications and precautions, and conditions incorrectly perceived as contraindications...



Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People™

Search

Vaccine Recommendations and Guidelines of the ACIP

ACIP Recs Home > Comprehensive Recommendations and Guidelines > General Best Practice Guidelines

ACIP Recs Home

Vaccine-Specific + Recommendations

Recs Listed by Date

Comprehensive Recommendations and Guidelines

Contraindications and Precautior

General Best Practice Guidelines for Immunization

<u>Print</u>

Updated August 1, 2023

Printer friendly version **[21** pages]

General Best Practice Guidelines

Updates

Major changes to the best practice guidance in this section include 1) enha

 \leftarrow

TABLE 4-1. Contraindications and precautions used vaccines

Vaccine	Citation	Contraindications	Pr
Dengue– ONLY use in persons who have laboratory confirmation of previous dengue infection AND reside in endemic dengue areas ^(b)	(<u>38</u>)	Lack of laboratory evidence of previous dengue infection Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long- term immunosuppressive therapy ^(c) or patients with HIV infection who are severely immunocompromised)	Pr HI ev in M illi
DT, Td	(<u>4</u>)	Severe allergic reaction (e.g.,	GI

TABLE 4-1. Contraindications and precautions^(a) to commonly used vaccines

Vaccine	Citation	Contraindications	Precautions
Dengue– ONLY use in persons who have laboratory confirmation of previous dengue infection AND reside in endemic dengue areas ^(b)	(<u>38</u>)	Lack of laboratory evidence of previous dengue infection Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long- term immunosuppressive therapy ^(c) or patients with HIV infection who are severely immunocompromised)	Pregnancy HIV infection without evidence of severe immunosuppression Moderate or severe acute illness with or without fever
DT, Td	(<u>4</u>)	Severe allergic reaction (e.g.,	GBS <6 weeks after

One to three contraindications

- One to three precautions
- One each for each of the hepatitis A and B vaccines
- Three and four respectively for the MMR vaccine

Hepatitis A	(<u>40</u>)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component	Moderate or severe acute illness with or without fever
Hepatitis B	(<u>41</u>)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component Hypersensitivity to yeast	Moderate or severe acute illness with or without fever
Hib	(<u>42</u>)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component Age <6 weeks	Moderate or severe acute illness with or without fever
HPV ^(d)	(<u>43</u>)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component, including yeast	Moderate or severe acute illness with or without fever

True Contraindications to the Hepatitis B Vaccine

- Severe allergic reaction (e.g., anaphylaxis)
 - After a previous dose
 - Or to a vaccine component
- Hypersensitivity to yeast

Common False Contraindications to the HepB Vaccine

- Pregnancy
- Autoimmune disease

True Contraindications to the HPV Vaccine

- Severe allergic reaction (e.g., anaphylaxis)
 - After a previous dose
 - Or to a vaccine component

Common False Contraindications to the HPV Vaccine

- Immunosuppression
- Previous equivocal or abnormal Papanicolaou test
- Known HPV infection
- Breastfeeding
- History of genital warts

			Pregnancy Latex sensitivity (MenB-4c)
MMR ^{(j),(k)}	(1)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component Pregnancy Known severe immunodeficiency (e.g., from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long- term immunosuppressive therapy ^(c) or patients with HIV infection who are severely immunocompromised) Family history of altered immunocompetence ^(m)	Recent (≤11 months) receipt of antibody- containing blood product (specific interval depends on product) History of thrombocytopenia or thrombocytopenic purpura Need for tuberculin skin testing or interferon- gamma release assay (IGRA) testing ^(I) Moderate or severe acute illness with or without fever
MPSV4	(<u>49</u>)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose	Moderate or severe acute illness with or without fever

True Contraindications to the MMR Vaccine

- Severe allergic reaction (e.g., anaphylaxis)
 - After a previous dose
 - Or to a vaccine component
- Pregnancy
- Known severe immunodeficiency
- Family history of altered immunocompetence^(m)

Common False Contraindications to the MMR Vaccine

- Positive tuberculin skin test
- Simultaneous tuberculin skin testing
- Breastfeeding
- Pregnancy of recipient's mother
- Female recipient of child-bearing age
- •

More Common False Contraindications

- .
- Immunodeficient household contact
- Asymptomatic or mildly symptomatic HIV infection
- Allergy to eggs

Footnotes Are Important with this Table

- Severe allergic reaction (e.g., anaphylaxis)
 - After a previous dose
 - Or to a vaccine component
- Pregnancy
- Known severe immunodeficiency
- Family history of altered immunocompetence^(m)

• Family history of altered immunocompetence^(m)

^(m) family history of congenital or hereditary immunodeficiency in first-degree relatives (e.g., parents and siblings), unless the immune competence of the potential vaccine recipient has been substantiated clinically or verified by a laboratory

(<u>52</u>)

Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures), not attributable to another identifiable cause, within 7 days of administration of previous dose of DTP, DTaP, or Tdap GBS <6 weeks after a previous dose of tetanustoxoid-containing vaccine Progressive or unstable neurological disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized

History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid containing or tetanustoxoid–containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanustoxoid–containing vaccine

Moderate or severe acute illness with or without fever

True Contraindications to the Tdap Vaccine

- Severe allergic reaction (e.g., anaphylaxis)
 - After a previous dose
 - Or to a vaccine component
- Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures), not attributable to another identifiable cause, within 7 days of administration of previous dose of DTP, DTaP, or Tdap

Common False Contraindications to the Tdap Vaccine

- Fever of < 40.5 °C, after a previous dose
- Fussiness or mild drowsiness after a previous dose
- Family history of seizures
- Family history of sudden infant death syndrome
- Family history of an adverse event after a dose
- Stable neurological condition

COVID-19's Contraindications Listed Elsewhere

- ACIP recommendations for COVID on interim pages
- Start at same starting point: cdc.gov/vaccines
- Look at special box on upper right
- Click there for recommendations & contraindications
- Click Healthcare Professionals and Jurisdictions
- •Then scroll down
- Click Interim Clinical Considerations



CDC Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People™

Search

Vaccines site •

Q

Español | Other Languages

Vaccines & Immunizations

Print

Table 1 Recommen	nded Child and Adolescent Im	nmunization Schedule for Ag	es 18 Years or Younger, United States, 2024	Table 1 Recommend	ded Adult Immunization Schedule by Age Group, U	Jnited States, 2024		COVID	10.)/
These recommendations must be rea To determine minimum intervals betwee	ad with the notes that follow, For those who fail (een down, see the catch-up schedule (Table 2).		m at the earliest opportunity as indicated by the green bars.	Vaccine	19-26 years 27-49 years	50-64 years	ad5 years	COVID	-19 Vaccination
Validation of the or a subscripting against factorization y specified when (81) is weld (Neuroscience)	Birth Tune 2 mas 6 mus 6 mus 1 dine depending on methodal Etit vasitination status, See Notes	Press 12 mes 15 mes 18 mes 14 Lioue 21 ferrough 18 membre, See Boltes	23ma 2-3yn 6-6yn 2-19yn 13-13yn 13-15yn 16yn 17-18y	COMD-19	1 ar mente doces cifoge	petaten (2023-2028 Fernada) vacane (See Notes)			
Pagetti 8 (Pagili)	1"dor +	7°804		Influenza inactivated (FPR) or Influenza recombinant (FI/4)	1 dicos an	rmaily			
Rotavirus (NV) NV1 (2-dece carino), NV3 (2-dece carino)	Phase Phase Section	-		Influenza ilive, attenuated	1 doce annually				
Digitativering terbenom, anallediar partonetic (DTath-C2 yrs)	Phone Phone Phone	Advanced to the second s	17 date	Respiratory Spraytial Vinas	Second alministration during programsy. See Notes		and press		Faulthalthanna Duafaasianala
Hannaphilas influenzes type & (HB)	Prison Prison Section	See Yorks		Tetanus, diphtheria, pertussis (Tdap or To	1 dose Tidap each programsy: 1 dose Tid70				For Healthcare Professionals
Presentosocial tentjogetis (PCVES, PCV20) Inactivated polarative (IPV cEllips)	Phone Phone Phone Phone Phone 4-	Pau		Maades, mamps, rubella (MMR)	1 dose Tdap, then Td or Tda T or 2 doses depending of born in 1957 o	n on indication	For healthcare personnel, see notes	20	and Jurisdictions
AND DESCRIPTION OF A DESCRIPTION		A second s	in a substantia and a	Notices Berg	The state of the state	1.1.4	20 F 20		
2024	Immur	nizatio	n Schedule	C The second second					
2027	mmmai	IIZacio	1 Schedule	Martin partitioners	CONTRACTOR CONTRACTOR				
Restalls (MR		display-a		Party and a second second		investore.	AND TRUCK OF THE		For Vou and Vour Forsily
Presente A Presid				Hepetital A.		Learn	More	Ť÷Ť	<u>For You and Your Family</u>
Theory of the section				No. of Concession, Name		which is set		AXA	
	N		100000						



Children (Birth to 18 Years)



Pregnancy and Vaccination

Clinical Resources for Each COVID-19 Vaccine

Product Information by U.S. Vaccine

- <u>6 Things to Know About the COVID-</u> <u>19 Vaccine for Children</u>
- <u>Resources to Promote COVID-19</u>
 <u>Vaccine for Children and Teens</u>



Enroll as a COVID-19 Vaccine Provider

Learn More and Enroll

Interim Clinical Considerations



Provider Requirements and Support



Talking with Vaccine Recipients



COVID-19 Tracking and Reporting Systems



COVID-19's Contraindications Listed Elsewhere

- Now scroll to Safety
- Click Contraindications and Precautions

→ C A https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

ર∕≡

Ð

 \sim

•••

Guidance for people who are **not** immunocompromised

Implementation

Timing, spacing, age transitions, and simultaneous administration

Interchangeability of COVID-19 vaccines

Vaccination and SARS-CoV-2 laboratory testing

Patient counseling

Safety				
Contraindications and precautions	Safety considerations for Novavax COVID- <mark>19</mark> Vaccine			
Reporting of vaccine adverse events	COMP 10 vector and muccorditic and			
Safety considerations for mRNA COVID-19 vaccines: Moderna and Pfizer-BioNTech	COVID-19 vaccination and myocarditis and pericarditis			

Special Situations and Populations

Table 3. Contraindications and precautions to COVID-19 vaccination

Medical condition or history	Guidance	Recommended action		
History of a severe allergic reaction* (e.g., anaphylaxis ⁺) after a previous dose or to a component of the COVID-19	Contraindication	Do not vaccinate with the same COVID-19 vaccine type. [§]		
vaccine [‡]		May administer the alternate COVID-19 vaccine type. [§]		
		See <u>Considerations for people with a history</u> of allergies and allergic reactions for additional information.		
History of a diagnosed non-severe allergy* to a component of the COVID-19 vaccine [‡]	Precaution	May administer the alternate COVID-19 vaccine type.⁵		
History of a non-severe, immediate (onset less than 4 hours) allergic reaction* after administration of a previous dose of one COVID-19 vaccine type [§]	Precaution	For additional information, see <u>Considerations for people with a history of</u> <u>allergies and allergic reactions</u> .		
Moderate or severe acute illness, with or without fever	Precaution	<u>Defer vaccination</u> until the illness has improved.		
History of MIS-C or MIS-A	Precaution	See <u>COVID-19 vaccination and MIS-C and</u> <u>MIS-A</u> .		
History of myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine	Precaution	A subsequent dose of any COVID-19 vaccine should generally be avoided.		
		See <u>COVID-19 vaccination and myocarditis</u> and pericarditis.		

Abbreviations: MIS-C = multisystem inflammatory syndrome in children; MIS-A = multisystem inflammatory syndrome in adults

*Allergic reactions in Table 3 are defined as follows:

One True Contraindication to a Specific COVID Vaccine

- Severe allergic reaction (e.g., anaphylaxis)
 - After a previous dose to that specific vaccine
 - Or to a vaccine component in that vaccine

Common False Contraindications to COVID Vaccines

- Other allergies (pets, food, environmental, latex, etc.)
- Recent COVID infection
- Pregnancy
- Prematurity
- Congenital heart disease

Package Inserts Versus the ACIP Listings

- Significant mismatches
 - Indications versus recommendations
 - Listings of contraindications and precautions
- Package inserts result from Pharma's licensure studies
- The ACIP language result from further deliberation
 - Epidemiology, experience, post-licensure studies
 - Listings here more likely to be updated, corrected

Further Advantages of ACIP Listings

- Harmonized among the experts
- Subject to ongoing review
- Matches Vaccine Information Statements content
- For the most part, easily accessed in a single location
 - Start here cdc.gov/vaccines
 - End up at https://www.cdc.gov/vaccines/hcp/aciprecs/general-recs/contraindications.html#t-01

- Recognize common false contraindications
- Know the steps in finding the true contraindications
- Explain why the package inserts fail as resources